ArticleScience advances2025

Targeting the ATM-TRMT10A-BRCA1 axis confers synthetic lethality to PARP inhibition in metastatic castration-resistant prostate cancer.

Ying Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.